首页 | 本学科首页   官方微博 | 高级检索  
     


The systemic treatment of recurrent ovarian cancer revisited
Affiliation:1. Department of Gynecology and Gynecological Oncology, Kliniken Essen-Mitte, Essen, Germany;2. Department of Oncology, KU Leuven, Leuven, Belgium;3. Department of Clinical and Experimental Medicine, Division of Gynecology and Obstetrics, Mauriziano Hospital, Turin, Italy;4. Department of Gynecology with Center for Oncological Surgery, Charité—University hospital Berlin, Berlin, Germany;5. Department of Oncology, St. James''s Hospital, Dublin, Ireland;6. Medical Oncology Department, Clínica Universidad de Navarra University Hospital, Madrid, Spain;7. Department of Oncology, Centre Francois Baclesse, Caen, France;8. Department of Medical Oncology, Academic Medical Center Amsterdam, Amsterdam, The Netherlands;9. Department of Gynecologic Oncology, Center of Oncology, M. Sklodowska-Curie Institute, Krakow, Poland;10. Department of Haematology-Oncology, National University Cancer Institute of Singapore, Singapore;11. Yong Loo Lin School of Medicine, National University of Singapore, Singapore;12. Department of Surgical Oncology, Institut Bergonié, Bordeaux, France;13. Department of Medicine and Surgery, European Institute of Oncology IRCCS, Milan, Italy;14. University of Milan-Bicocca, Milan, Italy;15. Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
Abstract:
Keywords:recurrent ovarian cancer  platinum-based chemotherapy  platinum re-treatment  poly(ADP-ribose) polymerase (PARP) inhibitor
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号